Pipeline· August 19, 2026 · 20 min read
Avexitide LUCIDITY Phase 3: What the First GLP-1 Antagonist Means for PBH Access
By Ran Chen#Pipeline#GLP-1#Clinical Evidence
Topic
Pivotal Trials
Registrational studies, trial design, primary endpoints, comparator choices, and evidence packages behind approvals.
Pipeline· August 19, 2026 · 16 min read
INTerpath-001 Phase 3: Intismeran Autogene and Keytruda's Post-2028 Strategy
By Ran Chen#Pipeline#Clinical Evidence#Pivotal Trials
Pipeline· July 26, 2026 · 18 min read
Alzheimer's Disease Clinical Trials by the Numbers: 2026 Registry Analysis
Pipeline· July 2, 2026 · 17 min read
The Anti-Obesity Phase 3 Pipeline: Active Trials and Mechanisms
By Ran Chen#GLP-1#Weight Loss#Clinical Evidence
Approvals· July 2, 2026 · 18 min read
Lifyorli (Relacorilant) FDA Approval and Ovarian Cancer Access
By Ran Chen#FDA Approval#Pivotal Trials#Payer Criteria
Pipeline· June 13, 2026 · 15 min read
ClinicalTrials.gov competitor trial landscape: how launch teams map a crowded indication
Pipeline· June 13, 2026 · 12 min read
ClinicalTrials.gov by the numbers: 589K studies and a 58% Phase 3 results gap
Evidence· June 13, 2026 · 11 min read
EULAR 2026 readouts: CD40L lupus win, IL-17 beats IL-23, off-the-shelf cell therapy
By Ran Chen#Immunology#Clinical Evidence#Pivotal Trials
Pipeline· June 12, 2026 · 9 min read
Retatrutide Phase 3: -28.3% body weight, 45% lose ≥30%, new UTI signal at ADA 2026
By Ran Chen#GLP-1#GIP/GLP-1#Clinical Evidence
Pipeline· June 7, 2026 · 9 min read
Cytisinicline smoking cessation PDUFA preview: first new pharmacotherapy in 20 years
By Ran Chen#PDUFA Date#FDA Approval#Clinical Evidence